Keyword: MD Anderson Cancer Center
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
The Institut Pasteur spinoff hopes its anti-telomerase cancer vaccine could be useful in immuno-oncology combo therapies.
A new study finds that Merck’s Gardasil may provide additional protection not included in its official FDA label.
For years, the University of Texas' MD Anderson Cancer Center has used the Cancer Moonshot tagline without any challengers. That is, until two separate programs with similar names came along earlier this year.
Clinical and research work into combination therapies and immuno-oncology are the focus of a research pact between China's Jiangsu Hengrui and the MD Anderson Cancer Center in Texas.